SC 108
Latest Information Update: 25 Sep 2021
Price :
$50 *
At a glance
- Originator Scotia Holdings [CEASED]
- Class Antihyperlipidaemics; Antihypertensives; Antithrombotics
- Mechanism of Action Cholesterol inhibitors; Platelet aggregation inhibitors; Prostaglandin synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Coronary artery restenosis; Peripheral vascular disorders
Most Recent Events
- 04 Jul 2000 Discontinued-Clinical for Coronary artery restenosis (Unknown route)
- 04 Jul 2000 Discontinued-Preclinical for Peripheral vascular disorders in United Kingdom (Unknown route)
- 24 Jul 1997 Investigation in Coronary artery restenosis (Unknown route)